Phase I trial shows needle-free pan-Sarbecovirus vaccine is safe with modest immune responses
By
Saul N. Fausta,b,1 Send email to [email protected]
Summary
This article reports on a first-in-human Phase I clinical trial of pEVAC-PS, a computationally designed pan-Sarbecovirus vaccine delivered via needle-free intradermal injection. The vaccine, developed using DIOSynVax technology, aims to induce broad cross-protective immune responses across multiple Sarbecoviruses including SARS, SARS-CoV-2, and potential zoonotic threats. The trial found the vaccine to be safe and well-tolerated. While immunogenicity was modest in the context of substantial pre-existing immunity, participants developed measurable responses to conserved, vaccine-encoded sarbecovirus epitopes, supporting the feasibility of this antigen design strategy.
Source
bskyPhase I trial shows needle-free pan-Sarbecovirus vaccine is safe with modest immune responsesjournalofinfection.comKey quotes
· 3 pulledNeedle-free intradermal delivery of this novel computationally designed PanSarbeco vaccine was safe and well tolerated.
Although immunogenicity was modest in the context of substantial pre-existing immunity, participants developed measurable responses to conserved, vaccine-encoded sarbecovirus epitopes, supporting the feasibility of this antigen design strategy.
The pEVAC-PS vaccine was developed using Digitally Immune Optimised Synthetic Vaccine (DIOSynVax) technology and pre-clinically selected for the ability to induce broadly protective immune responses across the Sarbecoviruses.
You might also wanna read
Programming the immunological properties of mRNA vaccines for cancer
Undisclosed Deaths in the Pfizer mRNA Covid-19 Vaccine Trial [pdf]
The Vital Role of Polypropylene Makers in Protecting Healthcare Workers During COVID-19
The article reflects on the importance of polypropylene makers during the COVID-19 pandemic, specifically highlighting how N95 masks (made f
lesswrong.com·3mo ago
FDA Approves First 100% Effective HIV Prevention Drug with Global Impact
The article discusses the milestone approval of the first HIV prevention drug, lenacapavir (brand name Yeztugo), which offers 100% protectio
newatlas.com·10mo ago
Impact of Hydrogen Sulphide Gas on SARS-CoV-2 Replication in Host Cells: Study by Indian Institute of Science
A study from the Indian Institute of Science (IISc) explores the impact of hydrogen sulphide gas on restricting SARS-CoV-2 replication in ho
iisc.ac.in·11mo ago